PremiumThe FlyCellectar Biosciences reports FY24 EPS ($1.40), consensus ($1.57) Cellectar Biosciences sees cash runway into 4Q25 CLRB Earnings Report this Week: Is It a Buy, Ahead of Earnings? PremiumCompany AnnouncementsCellectar Biosciences Strategic Shift and Workforce Reduction Cellectar Biosciences downgraded to Perform from Outperform at Oppenheimer Cellectar Biosciences trading resumes PremiumCompany AnnouncementsCellectar Biosciences Reports Q3 2024 Financial Results Cellectar Biosciences reports Q3 EPS (40c), consensus (37c) Cellectar Biosciences sees cash runway into 2Q25 
